Program
Terbinafine
Also written as “MOB015B”, “terbinafine” and “Terbinafine Hydrochloride”.
Its studies are mostly in Onychomycosis · Erythema · Tinea Pedis · Mycoses · Fasting, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Moberg Pharma AB | 71 open or running | phase 3since Aug 4, 2016 | Mar 15, 2013 | none ahead |
| Novartis | 70 open or running | phase 3since Jun 30, 2005 | Nov 2, 1999 | none ahead |
| Almirall | 30 open or running | phase 3since Sep 8, 2015 | Sep 8, 2015 | none ahead |
| Celtic Pharma Development Services | 20 open or running | phase 3since Mar 19, 2010 | Mar 18, 2010 | none ahead |
| Dr. Reddy's Laboratories | 20 open or running | phase 1since Jan 26, 2011 | Jan 26, 2011 | none ahead |
| Hikma Pharmaceuticals | 20 open or running | no phasesince Jan 15, 2008 | Jan 15, 2008 | none ahead |
| Nitric BioTherapeutics | 20 open or running | phase 2since Mar 1, 2010 | Mar 1, 2010 | none ahead |
| Teva Pharmaceutical Industries | 20 open or running | phase 1since Jan 30, 2009 | Jan 30, 2009 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| GlaxoSmithKline | 10 open or running | phase 1since Jan 17, 2013 | Jan 17, 2013 | none ahead |
| nexmed-u-s-a-inc-subsidiary-of-apricus-biosciences-inc | 10 open or running | phase 1since Jun 3, 2008 | Jun 3, 2008 | none ahead |
| Onyx Axiom | 11 open or running | phase 2since Nov 20, 2025 | Nov 20, 2025 | Jan 2028phase 2 · NCT07382427 |
| united-laboratories | 10 open or running | phase 2since Jun 24, 2019 | Jun 24, 2019 | none ahead |
Also a collaborator on its studies: ppd-development-lp.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Nov 2, 1999.
- Mar 18, 2010Celtic Pharma Development Services's first study: phase 2 study in OnychomycosisNew to Celtic Pharma Development ServicesCeltic Pharma Development Services · NCT01790165 · 27 enrolled
- Mar 19, 2010Phase 3 study in OnychomycosisCeltic Pharma Development Services · NCT01145807 · 738 enrolled · United States
- Jan 26, 2011Dr. Reddy's Laboratories's first studies: 2 phase 1 studiesNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01286701, NCT01286688
- Sep 8, 2011Phase 3 study in Tinea PedisNovartis · NCT01433107 · 290 enrolled · China
- Nov 28, 2011Phase 2 study in OnychomycosisNitric BioTherapeutics · NCT01484145 · 25 enrolled · United States
- Jan 17, 2013GlaxoSmithKline's first study: phase 1 study in MycosesNew to GlaxoSmithKlineGlaxoSmithKline · NCT01772212 · 30 enrolled
- Mar 15, 2013Moberg Pharma AB's first study: phase 2 study in Distal Subungual OnychomycosisNew to Moberg Pharma ABMoberg Pharma AB · NCT01814020 · Sweden
- Sep 8, 2015Almirall's first studies: 2 phase 3 studies in OnychomycosisNew to AlmirallAlmirall · NCT02549001, NCT02547701
- Aug 4, 20162 phase 3 studies in Distal Subungual OnychomycosisMoberg Pharma AB · NCT02859519, NCT02866032
- Mar 21, 2017Phase 3 study in Onychomycosis of ToenailAlmirall · NCT03094468 · United States, Canada
- Aug 1, 20173 phase 1 studiesMoberg Pharma AB · NCT06369727, NCT06369675, NCT03244280
- Jun 24, 2019united-laboratories's first study: phase 2 study in Tinea PedisNew to united-laboratoriesunited-laboratories · NCT03999437 · 42 enrolled · Philippines
- Mar 4, 2022Phase 3 study in OnychomycosisMoberg Pharma AB · NCT05279846 · 350 enrolled · United States, Canada
- Nov 20, 2025Onyx Axiom's first study: phase 2 study in Onychomycosis of ToenailNew to Onyx AxiomOnyx Axiom · NCT07382427 · 200 planned
Ahead
- Jan 2028Primary completion: phase 2 study in Onychomycosis of ToenailOnyx Axiom · NCT07382427
TargetBeta
“Squalene monooxygenase inhibitor; Squalene monooxygenase inhibitor”ChEMBL 37, by rule
“Terbinafine is a long-licensed, generic antifungal drug that inhibits squalene epoxidase (SQLE), an enzyme that may play a role in prostate cancer progression.”study text, by rule · the study
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07382427Onychomycosis of Toenail | 2 | Not yet recruiting | Onyx Axiom | Jan 2028 | 200 |
| NCT05279846Onychomycosis · United States, Canada | 3 | Active, not recruiting | Moberg Pharma AB | Jan 2025 | 350 |
| NCT03999437Tinea Pedis · Philippines | 2 | UNKNOWN | united-laboratories | Dec 13, 2019 | 42 |
| NCT06369727Erythema · United States | 1 | Completed | Moberg Pharma AB | Feb 15, 2018 | 250 |
| NCT06369675Erythema · United States | 1 | Completed | Moberg Pharma AB | Nov 14, 2017 | 45 |
| NCT03244280Onychomycosis · United States | 1 | Completed | Moberg Pharma AB | Apr 23, 2018 | 20 |
| NCT03094468Onychomycosis of Toenail · United States, Canada | 3 | Withdrawn | Almirall | Oct 2019 | 0 |
| NCT02866032Distal Subungual Onychomycosis · Germany, Poland, United Kingdom | 3 | Completed | Moberg Pharma AB | Jun 10, 2020 | 452 |
| NCT02859519Distal Subungual Onychomycosis · United States, Canada | 3 | Completed | Moberg Pharma AB | Nov 13, 2019 | 365 |
| NCT02549001Onychomycosis · Belgium, Bulgaria, Czechia and more | 3 | Completed | Almirall | Sep 17, 2018 | 953 |
| NCT02547701Onychomycosis · Belgium, Germany, Italy and more | 3 | Completed | Almirall | Sep 2017 | 20 |
| NCT01814020Distal Subungual Onychomycosis · Sweden | 2 | Completed | Moberg Pharma AB | Jul 2014 | |
| NCT01772212Mycoses | 1 | Completed | GlaxoSmithKline | Mar 15, 2011 | 30 |
| NCT01484145Onychomycosis · United States | 2 | Completed | Nitric BioTherapeutics | Mar 2012 | 25 |
| NCT01433107Tinea Pedis · China | 3 | Completed | Novartis | Feb 2012 | 290 |
| NCT01286701Lecithin Cholesterol Acyltransferase Deficiency · Canada | 1 | Completed | Dr. Reddy's Laboratories | Feb 2002 | 18 |
| NCT01286688Fasting · Canada | 1 | Completed | Dr. Reddy's Laboratories | Feb 2002 | 36 |
| NCT01145807Onychomycosis · United States | 3 | UNKNOWN | Celtic Pharma Development Services | Feb 2012 | 738 |
| NCT01790165Onychomycosis | 2 | Completed | Celtic Pharma Development Services | Jan 2010 | 27 |
| NCT01080079Onychomycosis · United States, Canada | 2 | Completed | Nitric BioTherapeutics | Nov 2011 | 168 |
| NCT00833664Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2002 | 22 |
| NCT00833586Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jan 2002 | 28 |
| NCT00691184Onychomycosis · United States | 1 | Completed | nexmed-u-s-a-inc-subsidiary-of-apricus-biosciences-inc | Jun 2005 | 56 |
| NCT00648713Healthy · United States | 1 | Completed | Viatris | Mar 2004 | 36 |
| NCT00647647Healthy · United States | 1 | Completed | Viatris | Mar 2004 | 36 |
| NCT00602342Onychomycosis · United States | – | Completed | Hikma Pharmaceuticals | Apr 2004 | 30 |
| NCT00602251Onychomycosis · United States | – | Completed | Hikma Pharmaceuticals | Apr 2004 | 30 |
| NCT00459537Onychomycosis · Finland, France, Germany and more | 3 | Completed | Novartis | Jan 2009 | 1,029 |
| NCT00443898Onychomycosis · United States, Canada, Iceland | 3 | Completed | Novartis | Jun 2008 | 518 |
| NCT00443820Onychomycosis · United States, France, Germany | 3 | Completed | Novartis | Jun 2008 | 526 |
| NCT00117767Tinea Capitis · United States | 3 | Completed | Novartis | Mar 2006 | 720 |
| NCT00117754Tinea Capitis · United States | 3 | Completed | Novartis | 720 | |
| NCT00002394Candidiasis, Oral · United States | – | Completed | Novartis | 30 |
How it is read
Names in the registry
- “MOB015B”, 7 entries
- “terbinafine”, 4 entries
- “Terbinafine”, 3 entries
- “Terbinafine Hydrochloride”, 3 entries
- “Terbinafine HCl 250mg tablets”, 2 entries
Codes read as this program: P3058.
Conditions, from the studies’ own filings
- Onychomycosis, 19 studies
- Erythema, 2 studies
- Tinea Pedis, 2 studies
- Mycoses, 1 study
- Fasting, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.